Pfizer/$PFE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Ticker
$PFE
Sector
Primary listing
NYSE
Employees
81,000
Headquarters
Website
Pfizer Metrics
BasicAdvanced
$141B
13.08
$1.89
0.46
$1.71
6.94%
Price and volume
Market cap
$141B
Beta
0.46
52-week high
$28.56
52-week low
$20.92
Average daily volume
56M
Dividend rate
$1.71
Financial strength
Current ratio
1.158
Quick ratio
0.778
Long term debt to equity
64.858
Total debt to equity
69.703
Dividend payout ratio (TTM)
89.68%
Interest coverage (TTM)
6.26%
Profitability
EBITDA (TTM)
24,506
Gross margin (TTM)
73.82%
Net profit margin (TTM)
16.84%
Operating margin (TTM)
27.78%
Effective tax rate (TTM)
-2.23%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
5.25%
Return on equity (TTM)
12.17%
Valuation
Price to earnings (TTM)
13.078
Price to revenue (TTM)
2.201
Price to book
1.59
Price to tangible book (TTM)
-4.27
Price to free cash flow (TTM)
11.298
Free cash flow yield (TTM)
8.85%
Free cash flow per share (TTM)
2.192
Dividend yield (TTM)
6.90%
Forward dividend yield
6.94%
Growth
Revenue change (TTM)
13.53%
Earnings per share change (TTM)
-504.04%
3-year revenue growth (CAGR)
-14.26%
10-year revenue growth (CAGR)
2.85%
3-year earnings per share growth (CAGR)
-28.16%
10-year earnings per share growth (CAGR)
3.00%
3-year dividend per share growth (CAGR)
2.47%
10-year dividend per share growth (CAGR)
4.64%
What the Analysts think about Pfizer
Analyst ratings (Buy, Hold, Sell) for Pfizer stock.
Bulls say / Bears say
Pfizer raised its full-year profit outlook for 2025 after second-quarter revenue of $14.65 billion surpassed forecasts, driven by strong sales of Vyndaqel and Eliquis, highlighting solid momentum in its core business.
The nearly $7.3 billion takeover of Metsera gives Pfizer a leading spot in the fast-growing anti-obesity market thanks to Metsera’s GLP-1-based weight-loss products, expanding Pfizer’s drug pipeline.
Pfizer’s deal with the U.S. government includes a $70 billion pledge to domestic research, development, and manufacturing over three years, bolstering long-term innovation and supply chain stability.
Pfizer stopped developing its oral weight-loss drug candidate danuglipron due to safety issues, which delays its entry into the obesity market and lets rivals gain ground.
A September agreement requires Pfizer to match Medicaid drug prices to those in other developed countries, which could put pressure on U.S. pharmaceutical margins, even though there are tariff exemptions.
Even as Pfizer expands into the obesity market, it faces tough competition from Novo Nordisk and Eli Lilly, whose GLP-1 therapies already have strong brand presence, scale, and prescribing channels.
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Pfizer Financial Performance
Revenues and expenses
Pfizer Earnings Performance
Company profitability
Pfizer News
AllArticlesVideos
Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
Business Wire5 days ago
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
Business Wire1 week ago
Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Pfizer stock?
Pfizer (PFE) has a market cap of $141B as of October 28, 2025.
What is the P/E ratio for Pfizer stock?
The price to earnings (P/E) ratio for Pfizer (PFE) stock is 13.08 as of October 28, 2025.
Does Pfizer stock pay dividends?
Yes, the Pfizer (PFE) stock pays dividends to shareholders. As of October 28, 2025, the dividend rate is $1.71 and the yield is 6.94%. Pfizer has a payout ratio of 89.68% on a trailing twelve-month basis.
When is the next Pfizer dividend payment date?
The next Pfizer (PFE) dividend payment is scheduled for December 01, 2025.
What is the beta indicator for Pfizer?
Pfizer (PFE) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.